Pharmaceutics · 2024 · 20 citations · 43 references
PharmacyPharmaceuticsPharmacologyBioavailabilityDrug DeliveryNanoparticle Drug DeliveryDrug EncapsulationNanomaterials For Drug DeliveryNanomedicineNanoparticle FormulationsOral NanocarriersPeptide DeliveryEncapsulation EfficiencyGlucagon-like Peptide 1 Receptor AgonismNanocarrier Encapsulation EfficiencyNanoparticle Delivery VectorsNanoparticle-based Controlled ReleaseOral Drug Delivery FormulationsPeptide NanoparticlesSimulated Gastric Fluid
Liraglutide (LIRA) is a glucagon-like peptide-1 (GLP-1) receptor agonist renowned for its efficacy in treating type 2 diabetes mellitus (T2DM) and is typically administered via subcutaneous injections. Oral delivery, although more desirable for being painless and potentially enhancing patient adherence, is challenged by the peptide's low bioavailability and vulnerability to digestive enzymes. This study aimed to develop LIRA-containing zein-based nanoparticles stabilized with eudragit RS100 and chitosan for oral use (Z-ERS-CS/LIRA). These nanoparticles demonstrated a spherical shape, with a mean diameter of 238.6 nm, a polydispersity index of 0.099, a zeta potential of +40.9 mV, and an encapsulation efficiency of 41%. In vitro release studies indicated a prolonged release, with up to 61% of LIRA released over 24 h. Notably, the nanoparticles showed considerable resistance and stability in simulated gastric and intestinal fluids, suggesting protection from pH and enzymatic degradation. Pharmacokinetic analysis revealed that orally administered Z-ERS-CS/LIRA paralleled the pharmacokinetic profile seen with subcutaneously delivered LIRA. Furthermore, in vivo tests on a diabetic rat model showed that Z-ERS-CS/LIRA significantly controlled glucose levels, comparable to the results observed with free LIRA. The findings underscore Z-ERS-CS/LIRA nanoparticles as a promising approach for oral LIRA delivery in T2DM management.
43
Pouya Saeedi, Inga Petersohn, Belma Malanda et al. · Diabetes Research and Clinical Practice · 2019 · 10.5K citations
Liraglutide in Children and Adolescents with Type 2 Diabetes
William V. Tamborlane, Margarita Barrientos‐Pérez, Udi Fainberg et al. · New England Journal of Medicine · 2019 · 347 citations · Full text
Medicine, Endocrinology, Pediatrics +12
Hari Hendarto, Toyoshi Inoguchi, Yasutaka Maeda et al. · Metabolism · 2012 · 227 citations · Full text